ActiveBiotech

30 JUNE 2026 08:30:00 CEST

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech AB (publ) has changed as a result of the reverse share split resolved by the Annual General Meeting.

Today, the last trading day of the month, there are in total 26,360,671 shares and votes in Active Biotech.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, [email protected]

Hans Kolam, CFO, +46 46 19 20 44, [email protected]

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. Laquinimod is in development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-06-30 08:30 CEST.

Attachments

Number of shares and votes in Active Biotech

ACTIVE BIOTECH AB (ORG.NR. 556223-9227) / SCHEELEVÄGEN 22, SE-223 63 LUND / +46 46-19 20 00 / WWW.ACTIVEBIOTECH.COM